Buy Max India, says Abhishek Agarwal of Fortune Interfinance.
Agarwal told CNBC-TV18, "I continue to remain bullish on Max India, therefore it is a buy. The target would be Rs 190 with a stop loss of Rs 173. I believe Rs 516 crore would be lucratively utilized in the healthcare space. Since the company plays both in insurance and healthcare, it will be a positive for the stock in the long term."
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
